Biochim Biophys Acta. 2014 Nov;1843(11):2620-30. doi: 10.1016/j.bbamcr.2014.07.012. Epub 2014 Jul 30.

Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma.

Biochimica et biophysica acta

Tzu-Pei Chang, Ivana Vancurova

PMID: 25089799 PMCID: PMC4158825 DOI: 10.1016/j.bbamcr.2014.07.012

Abstract

The advanced stages of cutaneous T cell lymphoma (CTCL) are characterized not only by decreased levels of pro-inflammatory cytokines, resulting in high susceptibility to infections, but also by high constitutive activity of NFκB, which promotes cell survival and resistance to apoptosis. The increased expression of the proto-oncogene Bcl3 belonging to IκB family is associated with the pathogenesis of the different types of human cancer, yet, the function and regulation of Bcl3 in CTCL have not been studied. Here, we show that Bcl3 is highly expressed in CTCL Hut-78 and HH cells. The suppression of Bcl3 levels decreases the expression of the pro-survival genes cIAP1 and cIAP2, reduces cell viability, and increases CTCL apoptosis. Interestingly, Bcl3 suppression concomitantly increases expression and the release of the pro-inflammatory cytokines IL-8 and IL-17 in CTCL cells. Chromatin immunoprecipitation studies show that Bcl3 regulates cIAP1, cIAP2, IL-8 and IL-17 gene expression through direct binding to their promoters. Bcl3 expression is regulated by bortezomib (BZ)-mediated proteasome inhibition, and BZ inhibits Bcl3 recruitment to its target promoters, resulting in decreased expression of cIAP1 and cIAP2, but increased expression of IL-8 and IL-17. The Bcl3 expression is regulated through NFκB subunit exchange on Bcl3 promoter. In untreated cells, the Bcl3 promoter is occupied predominantly by p65/p50 heterodimers, inducing Bcl3 expression; however, in BZ-treated cells, the p65/50 heterodimers are replaced by p52 subunits, resulting in Bcl3 transcriptional repression. These data provide the first insights into the function and regulation of Bcl3 in CTCL, and indicate that Bcl3 has an important pro-survival and immunosuppressive role in these cells.

Copyright © 2014 Elsevier B.V. All rights reserved.

Keywords: Bcl3; Bortezomib; Cutaneous T-cell lymphoma; NFκB; Pro-inflammatory cytokine

References

1. J Immunol. 2003 Oct 15;171(8):4210-8 - PubMed
2. Br J Dermatol. 2013 Mar;168(3):504-12 - PubMed
3. Cancer Manag Res. 2012;4:75-89 - PubMed
4. Mol Cell Biol. 1994 Jun;14(6):3915-26 - PubMed
5. Curr Opin Hematol. 2005 Jul;12(4):273-8 - PubMed
6. Clin Lymphoma Myeloma. 2008 Dec;8 Suppl 5:S187-92 - PubMed
7. J Immunol. 2013 Sep 1;191(5):2837-46 - PubMed
8. Semin Hematol. 2012 Jul;49(3):258-62 - PubMed
9. Cell. 1990 Mar 23;60(6):991-7 - PubMed
10. Clin Cancer Res. 2013 Jul 15;19(14):3755-63 - PubMed
11. J Immunol. 1995 Feb 1;154(3):1491-8 - PubMed
12. Clin Cancer Res. 2008 Feb 1;14(3):901-11 - PubMed
13. Mod Pathol. 2004 Aug;17(8):911-7 - PubMed
14. Semin Oncol. 2007 Dec;34(6 Suppl 5):S21-8 - PubMed
15. J Am Acad Dermatol. 2001 Aug;45(2):208-16 - PubMed
16. J Clin Invest. 2011 Jan;121(1):265-76 - PubMed
17. J Biol Chem. 2014 Jan 31;289(5):2687-700 - PubMed
18. Hum Pathol. 2000 Dec;31(12):1482-90 - PubMed
19. Expert Rev Hematol. 2011 Oct;4(5):551-62 - PubMed
20. J Biol Chem. 2014 Mar 7;289(10):7059-7067 - PubMed
21. Curr Treat Options Oncol. 2000 Apr;1(1):43-50 - PubMed
22. Genes Chromosomes Cancer. 1997 Sep;20(1):64-72 - PubMed
23. J Invest Dermatol. 1991 Nov;97(5):818-23 - PubMed
24. Cell Rep. 2012 Oct 25;2(4):824-39 - PubMed
25. Genes Dev. 1992 Dec;6(12A):2352-63 - PubMed
26. Mediators Inflamm. 2005 Oct 24;2005(5):273-9 - PubMed
27. Oncogene. 2006 Oct 30;25(51):6831-43 - PubMed
28. Curr Opin Oncol. 2009 Mar;21(2):131-7 - PubMed
29. Cell. 1993 Mar 12;72(5):729-39 - PubMed
30. Mol Cancer. 2011 Dec 23;10:152 - PubMed
31. J Dermatol. 2014 Jan;41(1):11-8 - PubMed
32. Eur J Haematol. 2009 Jun;82(6):440-9 - PubMed
33. Science. 2007 Aug 3;317(5838):675-8 - PubMed
34. Leukemia. 2012 Mar;26(3):424-32 - PubMed
35. J Clin Immunol. 2009 Mar;29(2):210-4 - PubMed
36. J Hematol Oncol. 2012 May 17;5:24 - PubMed
37. J Biol Chem. 2001 Aug 24;276(34):32080-93 - PubMed
38. Cancer Invest. 2004;22(2):304-11 - PubMed
39. Nature. 1992 Aug 13;358(6387):597-9 - PubMed
40. J Virol. 2001 Jul;75(13):6209-11 - PubMed
41. Cancer Biol Ther. 2011 Dec 15;12(12):1019-22 - PubMed
42. J Immunol. 2014 Mar 15;192(6):2913-9 - PubMed
43. Br J Haematol. 2011 Oct;155(2):150-66 - PubMed
44. Cancer Res. 1999 Jun 1;59(11):2615-22 - PubMed
45. J Virol. 2005 Dec;79(24):15302-13 - PubMed
46. J Clin Invest. 2005 Apr;115(4):798-812 - PubMed
47. Mol Cancer Res. 2011 Feb;9(2):183-94 - PubMed
48. Am J Hematol. 2011 Nov;86(11):928-48 - PubMed
49. Blood. 2005 Dec 15;106(13):4287-93 - PubMed
50. Cancer Res. 2013 Jan 15;73(2):745-55 - PubMed
51. Blood. 2006 Mar 15;107(6):2354-63 - PubMed
52. Mol Cell Biol. 1993 Jun;13(6):3557-66 - PubMed
53. Leukemia. 2009 Nov;23(11):1964-79 - PubMed
54. Blood. 2005 Feb 15;105(4):1640-7 - PubMed
55. Blood. 2006 Jul 1;108(1):401-2; author reply 402-3 - PubMed
56. Nucleic Acids Res. 1998 Jan 1;26(1):362-7 - PubMed
57. Mol Cell Biol. 2009 Aug;29(15):4091-102 - PubMed
58. J Clin Oncol. 2007 Sep 20;25(27):4293-7 - PubMed
59. Cancer Res. 2009 Mar 15;69(6):2365-74 - PubMed
60. Arch Biochem Biophys. 2008 Jul 15;475(2):156-63 - PubMed
61. Clin Cancer Res. 2008 Feb 1;14(3):646-53 - PubMed
62. Am J Cancer Res. 2013 Nov 01;3(5):433-45 - PubMed
63. Lymphokine Cytokine Res. 1994 Feb;13(1):21-7 - PubMed
64. Eur J Haematol. 2009 May;82(5):354-63 - PubMed
65. J Biol Chem. 1999 Oct 1;274(40):28491-6 - PubMed
66. J Virol. 2008 Dec;82(23):11939-47 - PubMed
67. Blood. 2013 Aug 8;122(6):943-50 - PubMed
68. J Invest Dermatol. 2011 Jun;131(6):1331-8 - PubMed

Publication Types

• Journal Article

Grant support

• R15 AI085497/AI/NIAID NIH HHS/United States
• R15 CA173452/CA/NCI NIH HHS/United States